New England Journal of Medicine· 2016Q1· Clinical trial

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, Peter Lommer Kristensen et al.

7,419citations
Q1SCImago
2016year

Short summary

In patients with type 2 diabetes and high cardiovascular risk, liraglutide significantly reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine